ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's …
WEB16 hours ago · Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared with treatment with Comirnaty. ... ARCT-154. Following the news, the stock ...
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT ...
WEBApr 20, 2022 · Forty-one cases occurred in the placebo group and 2 occurred in the ARCT-154 vaccinated group, demonstrating point estimate of vaccine efficacy of 95% against severe (including fatal) COVID-19 disease.
First self-amplifying mRNA vaccine approved - Nature
WEBJan 17, 2024 · The ARCT-154 vaccine was co-developed by Arcturus Therapeutics and CSL. The innovative sa-mRNA vaccine enables host cells in the body to make copies of the mRNA which encodes viral replicase...
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior …
WEB1 day ago · ARCT-154 12-month Study Design and Results The randomized, double-blind, active-controlled Phase 3 study was conducted at 11 clinical sites in Japan.
Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT …
WEBMay 14, 2024 · ARCT-154 vaccination is well tolerated, immunogenic and efficacious, particularly against severe COVID-19 disease.
Arcturus Therapeutics Reports New Data and Provides Additional …
WEBDec 16, 2021 · Preliminary data from ongoing clinical booster study of ARCT-154 (5 mcg) shows a 50-fold increase in neutralizing antibody geometric mean concentration against SARS-CoV-2 using a validated pseudovirus microneutralization (MNT) assay. Additional data shows activity against several variants of concern and variants of interest upon boosting with ...
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non …
WEBDec 21, 2023 · The randomized, double-blind, active-controlled study, conducted at 11 sites in Japan, was designed to compare the immunogenicity and tolerability of the sa-mRNA vaccine ARCT-154 with Comirnaty®. Phase 3 Study published in …
Self-copying RNA vaccine wins first full approval: what’s next?
WEBDec 6, 2023 · When used as a booster in clinical testing, the newly authorized vaccine, ARCT-154 — developed by Arcturus Therapeutics in San Diego, California, and its partner CSL, a biotechnology firm ...
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior …
WEB1 day ago · At Day 29, neutralizing antibodies (GMTs unadjusted) against the Wuhan-Hu-1 strain in ARCT-154 recipients (n = 378) were superior to those in the Comirnaty ® group (n = 374): GMT = 5390 (95% CI ...
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non …
WEBDec 21, 2023 · CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster. Study conducted by Meiji Seika Pharma in Japan.